15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse
about
Kir3 channel signaling complexes: focus on opioid receptor signalingA Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.Commonalities and Distinctions Among Mechanisms of Addiction to Alcohol and Other DrugsMisuse of Novel Synthetic Opioids: A Deadly New Trend.Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data.Expression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula.Whole-genome expression profile in zebrafish embryos after chronic exposure to morphine: identification of new genes associated with neuronal function and mu opioid receptor expression.The effects of beta-endorphin: state change modification.Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.The kappa opioid receptor: from addiction to depression, and back.Recent advances on the δ opioid receptor: from trafficking to function.In vivo opioid receptor heteromerization: where do we stand?Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type miceIn vivo neuronal co-expression of mu and delta opioid receptors uncovers new therapeutic perspectives.Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1The opioid receptors as targets for drug abuse medicationFulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Impact of chronic morphine on delta opioid receptor-expressing neurons in the mouse hippocampusNeuropeptidomics Mass Spectrometry Reveals Signaling Networks Generated by Distinct Protease Pathways in Human Systems.Molecular Pharmacology of δ-Opioid Receptors.Genes and Alcohol Consumption: Studies with Mutant Mice.The role of δ-opioid receptors in learning and memory underlying the development of addiction.Endogenous opioid system: a promising target for future smoking cessation medications.A gene-by-sex interaction for nicotine reward: evidence from humanized mice and epidemiology.Effects of genetic deletion of endogenous opioid system components on the reinstatement of cocaine-seeking behavior in mice.Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking.Reversal of stress-induced social interaction deficits by buprenorphine.Genetic dissociation of morphine analgesia from hyperalgesia in mice.Diversity of Neuropeptide Cell-Cell Signaling Molecules Generated by Proteolytic Processing Revealed by Neuropeptidomics Mass Spectrometry.Monoamines differentially modulate neuropeptide release from distinct sites within a single neuron pair.Human brain gene expression profiles of the cathepsin V and cathepsin L cysteine proteases, with the PC1/3 and PC2 serine proteases, involved in neuropeptide production.
P2860
Q27006957-2EEFBE8C-4ADC-4019-B921-5A9EF643A294Q28068256-2ACB1B4B-ADD8-4E37-A971-B90763105BADQ28080974-7124EF54-3CC5-4BF7-ADDE-741FA18345FAQ30491920-8A460A96-D0F5-4685-B222-8111B90FB75DQ30998741-1ECBC121-02EA-4BD0-8C7E-869C12E96872Q34183878-2A98DDBE-F3DC-43E7-AE45-6C05BA3A126CQ34363541-E65E5627-C9D5-446F-A2A3-B4FA7278AE51Q34471988-D715405F-40AD-4BA7-BB49-2CA75C81A9A6Q34538336-5AE0FB97-C7F5-499E-8D63-C144593A06C7Q34650892-CDC16FDF-681C-424B-9F3F-5E64C02F02C3Q34939664-F37D08A7-97FA-41DD-8F33-9E2DCD099353Q34939677-CFD7FFBB-79C3-4D2D-975E-980253D4B3D1Q35053193-2B41F597-CDD1-4744-A806-89DA89D2A909Q35199976-1DBD48C9-041D-4305-A5F3-819B45678235Q35557479-23C55D4A-7940-4699-8A83-702EA10986F9Q35901259-92A5B117-541E-4E98-B2D7-2F6371A32B32Q35978068-3CE0E4F4-C0A6-4E7D-995A-02FEE034D97FQ35999789-DBBEF709-E780-40A0-8A33-7CC8444F1CE4Q36104010-83534211-7794-4FD2-A748-AA746E8676E2Q36414746-89FC6077-6CB8-4D45-8911-4A64BFAA0CD1Q36568097-79EB08F2-11BA-4DC2-90DD-E7A025FE5003Q37062556-DFD59EDB-AB67-48F2-8BF1-4C565CAD28E9Q37635751-410C3832-5CBF-4CBF-910F-9526B38780C3Q38196926-17829F1D-2856-4855-B6E8-C4561AF4385DQ38747115-71C91AA2-D817-4358-B2D9-458C1C09BBABQ41271163-1C467DDC-06C6-4084-A3D9-DF0C6C45EB73Q43003017-CDBF1AC6-BDFA-460B-A079-EF2E59FC93F8Q44343229-9A738D48-0477-4780-A929-009284771A83Q44350366-E9B41AD9-B130-4C57-90C4-614B4DDC069FQ47659749-BB7E41AC-4E8F-423D-9910-6150C50D5847Q47934009-55CEB686-CF64-4221-B4E0-17B866EE3CC7Q52581456-FC602A15-DC6F-445D-9D49-818E13095F8CQ54972216-95E353BE-9AD5-4705-BAC4-F99DFE985765Q55641667-01F2FF77-19D1-40E6-A9BE-A04B2E79F273
P2860
15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
15 years of genetic approaches ...... in mouse models of drug abuse
@ast
15 years of genetic approaches ...... in mouse models of drug abuse
@en
15 years of genetic approaches ...... in mouse models of drug abuse
@nl
type
label
15 years of genetic approaches ...... in mouse models of drug abuse
@ast
15 years of genetic approaches ...... in mouse models of drug abuse
@en
15 years of genetic approaches ...... in mouse models of drug abuse
@nl
prefLabel
15 years of genetic approaches ...... in mouse models of drug abuse
@ast
15 years of genetic approaches ...... in mouse models of drug abuse
@en
15 years of genetic approaches ...... in mouse models of drug abuse
@nl
P2093
P2860
P1433
P1476
15 years of genetic approaches ...... in mouse models of drug abuse
@en
P2093
Brigitte L. Kieffer
Katia Befort
Pauline Charbogne
P2860
P304
P356
10.1016/J.NEUROPHARM.2013.08.028
P407
P478
P577
2014-01-01T00:00:00Z